ANTX vs INCY
ANTX: AN2 Therapeutics is a clinical-stage biopharmaceutical company leveraging a proprietary boron chemistry platform to develop novel small-molecule drugs for infectious diseases and cancer. INCY: Incyte is a biopharmaceutical company focused on discovering and developing innovative medicines for oncology and inflammatory conditions.
Side-by-side fundamentals
| Metric | ANTX | INCY | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $3.56 | $116.62 | |
| Market cap | $134M | $23.6B | |
| P/E as of 2026-10-20 | n/a | 16.47 | |
| Net margin FY2025, SEC XBRL | n/a | +25.0% | |
| Operating margin FY2025, SEC XBRL | n/a | +29.5% | |
| ROE FY2025, SEC XBRL | -66.3% | +24.9% | INCY higher |
| ROA FY2025, SEC XBRL | -56.8% | +18.5% | INCY higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +21.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +14.8% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.65 | 0.54 | |
| 1-year return as of 2026-10-20 close | +191.8% | +35.3% | ANTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.